Profile data is unavailable for this security.
About the company
Boundless Bio, Inc. is a clinical-stage oncology company, which is engaged in cancer therapeutics that address the unmet need in patients with oncogene amplified tumors by targeting extrachromosomal DNA (ecDNA). Using its proprietary Spyglass platform, it identifies targets essential for ecDNA functionality in oncogene amplified cancer cells, then designs and develops small molecule drugs called ecDNA-directed therapeutic candidates (ecDTx) to inhibit those targets. The Company’s lead therapeutic candidate ecDTx, BBI-355, is an oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells. BBI-355 demonstrated CHK1 inhibition and tumor regressions in oncogene amplified preclinical cancer models, including those enabled by ecDNA, and is being studied in a first-in-human, Phase I/II clinical trial in patients with oncogene amplified cancers. Its next program is directed at a previously undrugged kinesin target.
- Revenue in USD (TTM)0.00
- Net income in USD-61.76m
- Incorporated2018
- Employees64.00
- LocationBoundless Bio Inc10955 Alexandria Way, Suite 100SAN DIEGO 92121United StatesUSA
- Phone+1 (858) 766-9912
- Fax+1 (302) 655-5049
- Websitehttps://boundlessbio.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Aspira Women's Health Inc | 9.34m | -10.80m | 23.26m | 66.00 | -- | -- | -- | 2.49 | -0.3782 | -0.3782 | 0.3387 | -0.1018 | 1.55 | 11.79 | 7.26 | 141,469.70 | -179.16 | -116.24 | -903.68 | -168.65 | 63.90 | 50.98 | -115.66 | -287.59 | 1.32 | -189.81 | -- | -- | 0.3059 | 15.14 | 21.55 | -- | -22.58 | -- |
| Intensity Therapeutics Inc | 0.00 | -11.74m | 23.42m | 5.00 | -- | 2.65 | -- | -- | -0.638 | -0.638 | 0.00 | 0.1472 | 0.00 | -- | -- | 0.00 | -158.62 | -117.05 | -230.00 | -201.39 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -37.14 | -- | -- | -- |
| Senti Biosciences Inc | 0.00 | -47.58m | 23.89m | 34.00 | -- | 2.94 | -- | -- | -2.80 | -2.80 | 0.00 | 0.3089 | 0.00 | -- | -- | 0.00 | -86.19 | -50.97 | -106.55 | -57.59 | -- | -- | -- | -2,565.78 | -- | -- | 0.00 | -- | -100.00 | -- | 36.71 | -- | -58.03 | -- |
| Serina Therapeutics Inc | 130.00k | -18.59m | 23.99m | 12.00 | -- | -- | -- | 184.57 | -1.88 | -1.88 | 0.0133 | 0.1669 | 0.0131 | -- | -- | 10,833.33 | -187.74 | -188.54 | -- | -- | -- | -- | -14,331.54 | -7,513.03 | -- | -730.13 | 0.6444 | -- | -60.56 | -49.64 | 24.74 | -- | -49.05 | -- |
| IGC Pharma Inc | 1.11m | -6.45m | 24.28m | 70.00 | -- | 2.88 | -- | 21.95 | -0.078 | -0.078 | 0.0134 | 0.088 | 0.11 | 0.5489 | 26.02 | 15,800.00 | -64.10 | -51.04 | -81.62 | -56.88 | 46.20 | 43.57 | -582.82 | -1,150.02 | 0.889 | -- | 0.0165 | -- | -5.50 | -20.77 | 45.22 | -- | -35.93 | -- |
| Marker Therapeutics Inc | 4.69m | -14.30m | 24.68m | 5.00 | -- | 1.34 | -- | 5.26 | -1.23 | -1.23 | 0.3683 | 1.10 | 0.2876 | -- | 3.90 | 938,996.00 | -87.60 | -57.72 | -110.67 | -69.11 | -- | -- | -304.54 | -761.28 | -- | -- | 0.00 | -- | 99.06 | 98.63 | 23.60 | -- | -- | -- |
| Rallybio Corp | 674.00k | -14.17m | 24.82m | 15.00 | -- | 0.3909 | -- | 36.82 | -2.55 | -2.55 | 0.1203 | 12.02 | 0.0092 | -- | -- | 26,960.00 | -19.32 | -40.97 | -21.16 | -43.42 | -- | -- | -2,102.37 | -42,838.52 | -- | -- | 0.00 | -- | -- | -- | 22.52 | -- | -- | -- |
| Skye Bioscience Inc | 0.00 | -51.23m | 24.92m | -- | -- | 0.7336 | -- | -- | -1.29 | -1.29 | 0.00 | 1.06 | 0.00 | -- | -- | -- | -83.39 | -139.20 | -94.11 | -262.81 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 29.43 | -- | -- | -- |
| Aeon Biopharma Inc | 0.00 | -3.00k | 25.23m | 5.00 | 0.2156 | -- | 323.40 | -- | 4.87 | 4.87 | 0.00 | -1.71 | 0.00 | -- | -- | 0.00 | -0.0471 | -- | -- | -- | -- | -- | -- | -- | -- | -5.95 | -- | -- | -- | -- | 110.92 | -- | -- | -- |
| Cue Biopharma Inc | 7.10m | -37.68m | 25.42m | 41.00 | -- | 1.90 | -- | 3.58 | -0.4553 | -0.4553 | 0.0823 | 0.1703 | 0.1857 | -- | 4.01 | 173,170.70 | -98.58 | -60.20 | -170.74 | -73.56 | -- | -- | -530.75 | -683.99 | -- | -- | 0.1107 | -- | 69.16 | 21.84 | 19.83 | -- | 7.32 | -- |
| Boundless Bio Inc | 0.00 | -61.76m | 25.63m | 64.00 | -- | 0.2327 | -- | -- | -16.06 | -16.06 | 0.00 | 4.92 | 0.00 | -- | -- | 0.00 | -35.93 | -- | -38.37 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -32.22 | -- | -- | -- |
| Regentis Biomaterials Ltd | 0.00 | -5.20m | 25.97m | -- | -- | -- | -- | -- | -1.00 | -1.00 | 0.00 | -1.87 | 0.00 | -- | -- | -- | -1,548.81 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 226.60 | -- | -- | -- |
| IO Biotech Inc | 0.00 | -88.35m | 26.82m | 80.00 | -- | 28.52 | -- | -- | -1.34 | -1.34 | 0.00 | 0.0131 | 0.00 | -- | -- | 0.00 | -136.03 | -58.51 | -184.96 | -64.76 | -- | -- | -- | -- | -- | -- | 0.9482 | -- | -- | -- | -10.93 | -- | -- | -- |
| Raphael Pharmaceutical Inc | 0.00 | -1.40m | 27.48m | 0.00 | -- | -- | -- | -- | -0.0723 | -0.0723 | 0.00 | -0.0644 | 0.00 | -- | -- | -- | -4,831.04 | -- | -- | -- | -- | -- | -- | -- | -- | -86.56 | -- | -- | -- | -- | -13.02 | -- | -- | -- |
| Evaxion A/S (ADR) | 7.65m | -5.42m | 27.50m | 46.00 | -- | -- | -- | 3.59 | -16.88 | -16.88 | 2.18 | -- | -- | -- | -- | 166,326.10 | -- | -96.54 | -- | -126.06 | -- | -- | -70.88 | -2,792.25 | -- | -- | -- | -- | 4,480.82 | -- | 52.24 | -- | -- | -- |
| Exicure Inc | 0.00 | -9.23m | 27.98m | 8.00 | -- | 4.04 | -- | -- | -3.07 | -3.07 | 0.00 | 1.09 | 0.00 | -- | -- | 0.00 | -71.27 | -44.45 | -94.78 | -60.08 | -- | -- | -- | -259.52 | -- | -- | 0.00 | -- | -- | -17.34 | 42.65 | -- | -- | -- |
Data as of Feb 10 2026. Currency figures normalised to Boundless Bio Inc's reporting currency: US Dollar USD
33.69%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Fidelity Management & Research Co. LLCas of 30 Sep 2025 | 3.09m | 13.82% |
| Citadel Advisors LLCas of 26 Nov 2025 | 830.94k | 3.71% |
| Sectoral Asset Management, Inc.as of 30 Sep 2025 | 678.57k | 3.03% |
| Citadel Securities LLCas of 26 Nov 2025 | 602.45k | 2.69% |
| The Vanguard Group, Inc.as of 31 Dec 2025 | 597.19k | 2.67% |
| Wellington Management Co. LLPas of 30 Sep 2025 | 556.23k | 2.49% |
| Stonepine Capital Management LLCas of 30 Sep 2025 | 413.45k | 1.85% |
| Alyeska Investment Group LPas of 30 Sep 2025 | 300.00k | 1.34% |
| Redmile Group LLCas of 30 Sep 2025 | 245.46k | 1.10% |
| Renaissance Technologies LLCas of 30 Sep 2025 | 223.56k | 1.00% |
More ▼
Data from 30 Sep 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
